HCW BIOLOGICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.5 USD | -6.46% |
|
-5.66% | +22.45% |
| Apr. 01 | HCW Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Apr. 01 | HCW Biologics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 56.74M |
|---|---|---|---|---|---|
| Net income 2024 * | -23M | Net income 2025 * | -29M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.63
x | P/E ratio 2025 * |
-2.73
x | Employees | 45 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 48.07% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -6.46% | ||
| 1 week | -5.66% | ||
| Current month | -14.29% | ||
| 1 month | -14.29% | ||
| 3 months | +30.43% | ||
| 6 months | -15.64% | ||
| Current year | +22.45% |
1 week
1.44
1.64
1 month
1.441.93
Current year
1.101.93
1 year
0.912.32
3 years
0.917.78
5 years
0.917.78
10 years
0.917.78
| Managers | Title | Age | Since |
|---|---|---|---|
Hing Wong
FOU | Founder | 70 | 18-04-01 |
Rebecca Byam
DFI | Director of Finance/CFO | 68 | 19-09-30 |
Peter Rhode
CTO | Chief Tech/Sci/R&D Officer | 66 | 19-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Scott Garrett
CHM | Chairman | 73 | 21-04-30 |
Hing Wong
FOU | Founder | 70 | 18-04-01 |
Rick Greene
BRD | Director/Board Member | 59 | 21-04-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 1.5 | -6.46% | 888 |
| 24-04-23 | 1.604 | -1.62% | 8,757 |
| 24-04-22 | 1.63 | +6.54% | 3,309 |
| 24-04-19 | 1.53 | -7.83% | 1,426 |
| 24-04-18 | 1.66 | +4.40% | 2,566 |
Delayed Quote Nasdaq, April 24, 2024 at 04:30 pm EDT
More quotes
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth factor-β and stimulate immune cells, targeting senescent cells and the SASP factors they secrete. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, and others.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.5
USD
Average target price
4
USD
Spread / Average Target
+166.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +22.45% | 56.74M | |
| -1.51% | 104B | |
| +3.22% | 97.42B | |
| +1.31% | 22.2B | |
| -16.53% | 21.23B | |
| -8.40% | 18.33B | |
| -42.33% | 16.35B | |
| -20.09% | 15.06B | |
| +5.47% | 13.98B | |
| +28.85% | 11.66B |
- Stock Market
- Equities
- HCWB Stock
